• Drug Response Metrics in Cancer Cell Models

  2026-08-22

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that drug-induced growth inhibition and cell death frequently occur together but differ in magnitude and timing. This framework helps researchers design cancer drug experiments that separate cytostatic effects from true cytotoxicity and apoptosis.

• Nadolol (SQ-11725): A Translational PK Lens

  2026-08-21

  Nadolol (SQ-11725) offers translational researchers more than a conventional beta-blockade model. Its non-selective receptor activity and OATP1A2 substrate profile create an opportunity to connect beta-adrenergic pharmacology with transporter-aware pharmacokinetic design, while recent disease-state research highlights why exposure and tissue distribution should be measured alongside phenotype.

• Anlotinib in IADSRCT: Case Evidence and Limits

  2026-08-20

  This case report and literature review describes tumor reduction and sustained clinical control after anlotinib in a patient with metastatic intra-abdominal desmoplastic small round cell tumor. Its main contribution is hypothesis generation for a rare cancer lacking standardized treatment, while the single-patient design limits causal and generalizable conclusions.

• Epalrestat: Aldose Reductase Inhibitor Workflows

  2026-08-20

  Epalrestat gives researchers a practical way to connect polyol pathway inhibition with oxidative stress and KEAP1/Nrf2 biology. This workflow-focused guide covers DMSO handling, cell and animal model design, mechanism-aware readouts, and troubleshooting for diabetic neuropathy research and Parkinson’s disease models.

• Anlotinib in Intra-Abdominal DSRCT

  2026-08-19

  The reference report describes the first published clinical experience of anlotinib in metastatic intra-abdominal desmoplastic small round cell tumor, with radiographic reduction of metastatic lymph nodes after four treatment cycles and continued disease control during maintenance. Its main contribution is hypothesis-generating clinical evidence for using a multi-target tyrosine kinase inhibitor in a rare tumor lacking standardized therapy, while also highlighting the limits of interpretation from a single case.

• CSBTA Pharmacokinetics in MASH Mice

  2026-08-19

  The reference study integrates pharmacokinetic profiling, tissue distribution, transporter assays, and metabolic-enzyme analysis to explain how HFHCD-induced MASH changes exposure to Corydalis saxicola Bunting total alkaloids. Its findings show that disease status and repeated dosing can increase systemic and hepatic accumulation of key alkaloids, providing a mechanistic framework for understanding pharmacokinetic variability in MASLD/MASH treatment.

• Ruthenium Red in Calcium Signaling Research

  2026-08-18

  Ruthenium Red is a water-soluble Ca2+ transport inhibitor for dissecting membrane calcium flux, mitochondrial calcium uptake, sarcoplasmic reticulum function, and mechanically induced signaling. This practical guide connects its use with cytoskeleton-dependent autophagy assays while emphasizing controls, solution handling, and interpretation limits.

• Sabutoclax for Apoptosis Response Assays

  2026-08-18

  Sabutoclax is a cell-permeable pan-Bcl-2 inhibitor for dissecting target engagement, growth suppression, and apoptosis in cancer models. This workflow pairs concentration-response profiling with time-resolved death measurements so researchers do not confuse metabolic arrest with genuine cell killing.

• SU5416: From VEGFR2 Blockade to PAH Models

  2026-08-17

  SU5416, also known as Semaxanib, is more than a cancer research angiogenesis inhibitor: it is a valuable tool for interpreting how VEGFR2 blockade reshapes vascular biology. This article connects its mechanism with proteomic biomarker research in pulmonary arterial hypertension while clarifying model-specific assay and dosing decisions.

• Mithramycin A: Mechanism and Research Workflow

  2026-08-17

  Mithramycin A is an anticancer antibiotic that binds G-C-rich DNA in the presence of divalent metal ions and can suppress transcriptional programs such as c-myc. This article defines its molecular rationale, evidence boundaries, and practical workflow for leukemia research and cancer biology research.

• Dacomitinib in Cancer Research: Workflow Guide

  2026-08-16

  Build a practical Dacomitinib workflow for linking irreversible ErbB signaling blockade with apoptosis, cell-cycle, and mitochondrial stress assays. The guide also shows how PF-00299804 can be used as a mechanistic perturbation in HER2-amplified breast cancer research, EGFR-driven lung models, and exploratory ferroptosis studies.

• E-4031 for 3D Cardiac Electrophysiology

  2026-08-15

  E-4031 provides a precise pharmacological challenge for hERG-dependent repolarization studies, including 3D organoid assays that go beyond conventional planar recordings. Paired with shell microelectrode arrays and calcium imaging, it helps connect QT interval prolongation-like electrical changes with spatial conduction and arrhythmogenic behavior.

• AO/PI Double Staining Kit for Cell Fate Profiling

  2026-08-14

  The AO/PI Double Staining Kit provides a rapid fluorescent readout that separates viable, apoptotic, and necrotic cells in one workflow. It is especially useful for drug-response screening, organoid studies, and post-isolation quality control where membrane integrity and cell-state differences must be assessed quickly.

• A-1210477: Mapping MCL-1 Dependency

  2026-08-14

  A-1210477 is a selective MCL-1 inhibitor for dissecting how cancer cells evade mitochondrial apoptosis. This guide develops a dependency-centered assay strategy that separates target-specific apoptotic rescue from nonspecific cytotoxicity and clarifies the compound’s in vitro research value.

• PAK1, mRNA Decay, and Oxaliplatin in Colorectal Cancer

  2026-08-13

  A recent Genes & Diseases study identifies PAK1 as a regulator of oncogenic mRNA stability in colorectal cancer, linking kinase activity to the persistence of several tumor-promoting factors. The work also reports strong synergy between the PAK1 inhibitor PF3758309 and Oxaliplatin, providing a mechanistic rationale for investigating PAK1-directed combination strategies in colorectal cancer models.

7907 records 1/528 page Next 12345 下5页 Last page